NasdaqGM - Nasdaq Real Time Price USD

Invivyd, Inc. (IVVD)

Compare
0.4520
-0.0095
(-2.06%)
At close: January 10 at 4:00:02 PM EST
0.4399
-0.01
(-2.68%)
After hours: 7:59:49 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IVVD

Recent News: IVVD

View More
What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?

What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?
Benzinga 23 hours ago
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
GlobeNewswire yesterday
Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media?

Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media?
Insider Monkey 4 days ago
Adagio Medical announces Todd Usen as new CEO and director

Adagio Medical announces Todd Usen as new CEO and director
Medical Device Network 25 days ago

Q3 2024 Invivyd Inc Earnings Call
Thomson Reuters StreetEvents last month

Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...
GuruFocus.com last month
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates

Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates
Zacks last month
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire last month
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
GlobeNewswire last month
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively
GlobeNewswire last month
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
GlobeNewswire 2 months ago
View More

Related Tickers

NBY NovaBay Pharmaceuticals, Inc.
0.6970
+9.16%
 
ELEV Elevation Oncology, Inc.
0.6504
-13.72%
 
GDTC CytoMed Therapeutics Limited
2.7600
+20.52%
 
SNSE Sensei Biotherapeutics, Inc.
0.5125
-3.30%
 
UNCY Unicycive Therapeutics, Inc.
0.6644
-10.81%
 
INAB IN8bio, Inc.
0.3233
+3.42%
 
NLSP NLS Pharmaceutics AG
2.3200
-3.73%
 
DTIL Precision BioSciences, Inc.
5.70
+26.67%
 
CYCC Cyclacel Pharmaceuticals, Inc.
0.4199
+1.21%
 
CDT Conduit Pharmaceuticals Inc.
0.1233
+50.37%